Chong Kun Dang Holdings Holds ‘CKD Trust Partner’s Day’ with Cooperative Companies

CEO Choi Hee-nam of Chong Kun Dang Holdings. (Photos: Chong Kun Dang)

Chong Kun Dang Holdings hosted the “CKD Trust Partner’s Day,” inviting CEOs and executives of some 50 cooperative companies of Chong Kun Dang and its subsidiaries.

The event took place at the Chong Kun Dang building in Chungjeong-ro, Seoul, on Nov. 19.

CEOs and executives of some 50 cooperative companies of Chong Kun Dang and its subsidiaries participate in the “CKD Trust Partner’s Day” at Chong Kun Dang headquarters in Seoul on Nov. 19.

It served as an opportunity for Chong Kun Dang Holdings, the holding company of Chong Kun Dang Group, and health care companies, including Chong Kun Dang, Chong Kun Dang Bio, Kyongbo Pharmaceutical and CKD Healthcare, as well as their cooperative companies to not only build consensus for practicing of ESG management, but also to promote shared growth and co-prosperity.

During the event, Chong Kun Dang Holdings, stressing the significance of ESG management, unveiled policies to manage the group’s supply chains, to be implemented next year.

The holding company announced plans to prevent and manage supply chain risks, such as supporting ESG management self-diagnosis.

Chong Kun Dang introduced its compliance program and implementation practices and took time to ask for participation and cooperation from its cooperative companies.

CEO Choi Hee-nam of Chong Kun Dang Holdings said, “We will build right relations for sustainable growth based on mutual trust and cooperation among companies and ram up fair trade, and from now on, Chong Kun Dang will continue to communicate with its cooperative companies and do its utmost to prevent and manage supply chain risks.”

New Drug for Dyslipidemia Gets Nod for 1st Phase Clinical Trial from FDA

Chong Kun Dang (CKD) said on Nov. 4 that it got the go-head from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 clinical trial for its new drug treating dyslipidemia, dubbed “CKD-508”, and to explore the optimal dose for its Phase 1 clinical trial.

During the trial, Chong Kun Dang plans to assure the safety and lipid-improving effects of CKD-508.

The drug aims to treat dyslipidemia by curbing the activity of Cholesteryl Ester Transfer Protein (CETP) to lower low-density lipoprotein cholesterol (LDL-C) and raising high-density lipoprotein cholesterol (HDL-C).

Hyojong Center at Chong Kun Dang said that during its non-clinical efficacy testing, CKD-508 has proven to have an effect of lowering LDL-C and raising HDL-C.

It also confirmed a dramatic decline in Apolipoprotein B (Apo-B), a major dyslipidemia index.

A Chong Kun Dang official said, “CKD-508 is an innovative drug, expected to have an efficacy at a low dose, based on strong binding power with CETP by solving the problems, such as drug accumulation and blood pressure rise, which halted the development of preceding CETP inhibitors, and if it is developed successfully, the drug is expected to become a treatment option for dyslipidemia patients that cannot be treated by statin drugs.”

Meanwhile, the value of the global dyslipidemia drug market, now standing at $8 billion (some 11 trillion won), is predicted to surge $20 billion (some 275 trillion won) by 2030.

An image of the dual multi-cap hangover reliever “Kaenoni Thankyou Shot,” launched by Chong Kun Dang.

Chong Kun Dang Releases Dual Multi-Cap Hangover Reliever

Chong Kun Dang said it launched the dual multi-cap hangover reliever “Kaenoni Thankyou Shot.”

The Kaenoni Thankyou Shot contains nonitri, a substance proved efficacious for relieving hangovers, and high doses of vitamins to improve vigor.

Nonitri effectively protects the liver and eases intestine troubles, by increasing beneficial bacteria and inhibiting of harmful bacteria.